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R
(Is Reclassification of
Intermediate-Risk Subjects
by Coronary Artery Calcium
Scoring Clinically Useful?
In a population-based cohort of 4,129 subjects without overt
coronary artery disease at baseline, Erbel et al. (1) demonstrated
that coronary artery calcium (CAC) scoring provides a significant
improvement in discrimination and a high level of correct reclas-
sification when applied to persons initially identified by the
Framingham criteria as having an intermediate risk for coronary
events. The investigators concluded that “limiting CAC scoring to
intermediate-risk subjects can contribute to reducing the number
of coronary events in the general population.” Because prediction
does not necessarily lead to prevention, we should scrutinize the
level of scientific evidence on the ability of CAC scoring to
improve health outcomes.
To reduce disease-specific morbidity or mortality, the process of
reclassification should be able to select subjects to more intensive
treatment of modifiable risk factors. According to results derived
from the investigators’ Table 3 (1), 77% of correct reclassification
n subjects with 10% to 20% risk was confined to down-
lassification of those without events. Obviously, this type of
eclassification does not induce physicians to enhance preventive
trategies. In contrast, there is no scientific evidence that it is safe
o downgrade preventive care on the basis of a low CAC score.
hus, 77% of correct reclassification obtained by CAC scoring
hould have no impact on clinical management and outcomes.
And what about up-classification of those with events, which took
lace in the remaining 23% of correct reclassification (1)? Should it
modify preventive strategies? Regarding statin therapy, a reduction in
coronary events has been recently demonstrated by aggressive lipid
lowering in intermediate-risk subjects with normal low-density lipo-
protein cholesterol levels (2). Thus, it is unlikely that CAC scoring
will modify the recommendations for statin therapy in this population.
Second, the indication for initiating drug therapy in patients with
hypertension and target blood pressure values should not differ
between intermediate-risk and high-risk subjects (3). Finally, should
spirin be used in subjects reclassified to high risk? The magnitude of
bsolute risk reduction of cardiovascular events by aspirin in primary
revention is small, and the risk/benefit ratio does not justify its use in
ost subjects (4). Recently, the long-term beneficial effect of aspirin
n patients with diabetes has been questioned in several randomized
linical trials (5), suggesting that aspirin is justified only for very
igh-risk patients, mostly in the secondary prevention setting. In
ddition, aspirin did not prove beneficial in a clinical trial focused on
symptomatic subjects with subclinical atherosclerosis assessed by
nkle-brachial index (6). Finally, lifestyle measures, such as smoking
essation, weight control, and exercise, are universally recommended,
egardless of risk profile. wTherefore, the utility of reclassifying intermediate-risk subjects
may be a questionable paradigm, and before implementing such a
strategy, the efficacy of using CAC scoring should be tested by
appropriate clinical trials comparing the incidence of cardiovascu-
lar events between subjects randomized to CAC scoring and those
randomized to no CAC scoring.
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Reply
We thank Drs. Correia and Rassi for their interest in our study (1)
and for addressing important issues for clinical decision making
using coronary artery calcium (CAC) scoring. Current strategies of
risk prediction are based predominantly on traditional risk factors
and have been proven very successful in populations. However, on
an individual level, misclassification is common. In 2010, 3 groups
independently published studies about the value of CAC scoring
for discrimination in the general population when added to
traditional risk factors: in MESA (Multi-Ethnic Study of Athero-
sclerosis), CAC scoring improved the discrimination of coronary
events including revascularization, with net reclassification im-
provement (NRI) of 25% (2); in the HNR (Heinz Nixdorf Recall)
study, CAC scoring improved the discrimination of hard coronary
events (i.e., cardiac death and myocardial infarction; NRI  30%)
1); and in the Rotterdam Study, hard coronary event prediction
as significantly improved in an elderly cohort (NRI  14%) (3).
R1082 Correspondence JACC Vol. 58, No. 10, 2011
August 30, 2011:1081–6The magnitude of this improvement exceeds that obtained from
other novel markers of risk (4), and these findings have contributed
to CAC scoring now being considered a Class IIa indication for
the purpose of risk stratification in intermediate-risk subjects (5).
We agree with Drs. Correia and Rassi that improvement in risk
prediction must not necessarily result in improved prevention. How-
ever, improved discrimination is an important step toward a more
effective utilization of resources that are directed at the prevention of
cardiovascular disease (CVD) events. At one end of this spectrum,
this process indeed aims “to select subjects to more intensive treatment
of modifiable risk factors.” In our study, correct reclassification
occurred in a similar magnitude in subjects with and without events
(i.e., 18% and 21%, respectively) and hence contributed similarly to
overall NRI. Drs. Correia and Rassi argue that correct down-
classification would not “induce physicians to enhance preventive
strategies.” What do they mean? Their statement is certainly true, if
it refers to an increased use of lipid-lowering, blood pressure–
lowering, or other preventive drugs. However, in our opinion,
preventive strategies are also “enhanced” when physicians em-
phasize the well-documented benefits of lifestyle modification
(6,7) and when many subjects in whom the preventive value of
drug-based risk modification is uncertain are prevented from an
unnecessary use of such drugs. This especially applies to the
intermediate-risk subjects. Our data imply that such subjects
with no or very low CAC scores are at sufficiently low risk that
the number needed to treat among these persons would be so high
that the benefit for outcomes would not further improve the
benefits expected from lifestyle modification. We agree with Drs.
Correia and Rassi that this hypothesis still needs to be proved.
The need for improved discrimination is supported by a recent
meta-analysis, which includes the JUPITER (Justification for the
Use of Statins in Prevention: An Intervention Trial Evaluating
Rosuvastatin) trial. The data suggest that statins may not relevantly
reduce all-cause mortality in high-risk primary prevention (8). In a
more recent Cochrane analysis, the magnitude of benefit from
statin therapy for disease-specific morbidity and mortality was also
judged to be lower than what has previously been suggested from
trials that included many patients with known coronary heart
disease and/or CVD (9,10). So, although intensive lipid lowering
is now an established concept to reduce CVD mortality and
morbidity across a wide range of subjects at risk, drug-based lipid
lowering seems to be particularly useful in high-risk subjects, who
must be identified somehow.
Drs. Correia and Rassi further refer to the JUPITER trial,
which demonstrated a benefit of rosuvastatin for CVD events in
low-risk to intermediate-risk persons with “normal” low-density
lipoprotein cholesterol but elevated high-sensitivity C-reactive
protein levels. In a recent analysis, we found that CAC scoring was
superior to high-sensitivity C-reactive protein for the discrimina-
tion of hard coronary events, but high-sensitivity C-reactive
protein added predictive information in persons with no or very
low CAC scores (11). In that same work, we also observed the
value of a combined assessment of signs of atherosclerosis burden
and signs of inflammation for the prediction of coronary events
and all-cause mortality (11). Different from Drs. Correia and
Rassi, we do see the possibility that the combined quantification of
atherosclerosis burden and of inflammatory biomarkers may in-
deed modify recommendations for the intensity of statin therapy in
selected populations and patients.
Although the contribution by Garg et al. (12) referenced by
Drs. Correia and Rassi does not say much about intermediate-risksubjects, the initiation and treatment goals of antihypertensive
medications, similar to the indications and goals of statin therapy,
also depend on the global risk burden (i.e., the number of risk
factors, presence of diabetes, and/or end-organ damage, including
established renal or CVD) (13). We obviously agree that hyper-
tension therapy is very important across all levels of risk in
primary prevention. This is supported by a recent publication
on the predictive role of CAC in low-risk to intermediate-risk
subjects without indications for statin therapy (14). Among
such subjects, those with CAC scores 400 were at much
higher risk, especially for stroke and revascularization, than
those with CAC scores 400 and were predominantly charac-
terized by arterial hypertension (14).
We also agree with Drs. Correia and Rassi that the use of
aspirin in primary prevention is under discussion and may not
always be as useful as frequently assumed.
In summary, we recommend not relying solely on risk factor
assessment at one point in time to estimate long-term CVD risk.
CAC scoring in carefully selected subjects takes into account the
lifelong variable risk factor exposure, which is reflected in the
extent of subclinical atherosclerosis. This allows targeted inten-
sive medical prevention beyond lifestyle modification, targeted
to high-risk subjects identified by traditional risk factors and by
atherosclerosis imaging. We strongly agree with Drs. Correia
and Rassi that the novel concepts derived from our findings
must be tested in an appropriate prospective clinical trial, which
is under way and supported by the National Institutes of
Health. In line with current expert consensus, we believe that
CAC scoring can be clinically useful today in those patients in
whom the benefit of drug-based risk factor therapy beyond
lifestyle modification is uncertain.
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Ranolazine and Silent Ischemia
I read with interest the paper by Stone et al. (1), in which the authors
investigated the relationship between ST-segment depression and the
rate-pressure product during exercise. Based on their findings, they
suggested that ranolazine’s beneficial action is most likely primarily
due to improvement of regional coronary blood flow in areas of
myocardial ischemia. I do not refute that statement, but I would like
to remind the readers that the current hypothesis of the mechanism of
action of ranolazine is that it works only after myocardial ischemia has
been present. When that happens, the late sodium channel remains
open, leading to intracellular sodium overload, and the sodium–
calcium exchanger then leads to intracellular calcium overload, which
results in increased calcium ions intracellularly and impaired diastolic
relaxation and increased tension. Ranolazine inhibits the myocardial
late inward sodium current associated with ischemia and thus breaks
up the cycle (2).
The authors emphasize in their article that under low stress conditions
of exercise where there was mild ischemia, the ranolazine did not seem to
be effective; however, as the ischemia became more pronounced, the
anti-ischemic effects of ranolazine became more marked.
My question to the investigators is this: Since it has been shown
many times that patients with chronic stable angina have multiple aepisodes of asymptomatic cardiac ischemia, is it possible or
probable that these multiple episodes of silent cardiac ischemia are
prevented from becoming manifest symptoms of myocardial isch-
emia (i.e., angina) by the drug ranolazine?
I suspect that the only way one could find the answer is to have
chronic ambulatory electrocardiogram (ECG) monitoring of these
patients. I know that patients who were in the MERLIN–TIMI
36 (Metabolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Segment Elevation Acute Coronary Syndromes–
Thrombolysis In Myocardial Infarction 36) trial (3) had 7 days of
ambulatory ECG monitoring, but the published study revealed
that only arrhythmias were assessed. Would it be possible to go
back and investigate those ambulatory ECGs to see whether or not
silent ST-segment depression was present on several occasions
without any manifestations of angina?
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Dr. Conti raises an interesting conceptual point regarding our paper
(1) concerning the implications of treatment with ranolazine. If
anolazine were to render each ischemic episode less severe than an
schemic episode in the absence of ranolazine, then despite a reduction
n symptomatic ischemia (i.e., angina), ranolazine may be associated
ith more frequent asymptomatic ischemia and, by inference, may
xpose the patient to an increased risk of cardiac events.
The fundamental premise implicit in this question, however,
hat asymptomatic episodes of myocardial ischemia represent less
evere ischemia than symptomatic episodes, has not been demon-
trated in any clinical study. Episodes of asymptomatic ischemia
ecorded during ambulatory electrocardiogram (ECG) recordings
emonstrate the same ECG characteristics of ischemia severity as
pisodes of symptomatic ischemia (2). There is no evidence to
upport the notion that asymptomatic ischemia is asymptomatic
ecause it is less severe than symptomatic ischemia and, conse-
uently, does not reach an “angina threshold.”
As Dr. Conti noted, patients in the MERLIN–TIMI 36 (Metabolic
fficiency With Ranolazine for Less Ischemia in Non–ST-Segment
levation Acute Coronary Syndromes–Thrombolysis In Myocardial
nfarction 36) trial had 7 days of continuous ECG recordings following
dmission with a non–ST-segment elevation acute coronary syndrome.
